Want to join the conversation?
$VRTX expects to provide net product revenue guidance for Orkambi during 2016. As of Dec. 31, more than 4,500 people had begun treatment in the U.S. since approval. $VRTX sees vast majority of eligible patients in the U.S. will begin treatment by end of 2016. $VRTX will recognize revenues from Orkambi sales in the U.S. and Germany in 2016.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?
$AVGO 4Q results beat analyst’s expectations again this time. Time to make some hay while the sun shines ;)